Literature DB >> 24084916

Pricing for orphan drugs: will the market bear what society cannot?

Brian P O'Sullivan1, David M Orenstein, Carlos E Milla.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24084916     DOI： 10.1001/jama.2013.278129

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  26 in total

1.  Breathing easier with combinations.

Authors:  Anna Azvolinsky
Journal:  Nat Biotechnol       Date:  2015-11       Impact factor: 54.908

2.  Pharmacoeconomics and the medicinal chemist.

Authors:  Craig W Lindsley
Journal:  ACS Med Chem Lett       Date:  2014-09-05       Impact factor: 4.345

3.  Foundation receives $3.3-billion windfall for Kalydeco.

Authors:  Melanie Senior
Journal:  Nat Biotechnol       Date:  2015-01       Impact factor: 54.908

Review 4.  Fair pricing of "old" orphan drugs: considerations for Canada's orphan drug policy.

Authors:  Eve A Roberts; Matthew Herder; Aidan Hollis
Journal:  CMAJ       Date:  2015-02-23       Impact factor: 8.262

5.  Orphan drug policies and use in pediatric nephrology.

Authors:  Diana Karpman; Peter Höglund
Journal:  Pediatr Nephrol       Date:  2016-10-13       Impact factor: 3.714

6.  Acquiring orphans.

Authors:  Rogier Rooswinkel; Geert-Jan Mulder; Sander van Deventer
Journal:  Nat Biotechnol       Date:  2014-03       Impact factor: 54.908

7.  Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation.

Authors:  Deborah M Cholon; Charles R Esther; Martina Gentzsch
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-04-22

8.  Respiratory pathogens mediate the association between lung function and temperature in cystic fibrosis.

Authors:  Joseph M Collaco; Karen S Raraigh; Lawrence J Appel; Garry R Cutting
Journal:  J Cyst Fibros       Date:  2016-06-11       Impact factor: 5.482

9.  Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine.

Authors:  Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; László Szilberhorn; Tamás Zelei; Balázs Nagy; Rositsa Koleva-Kolarova; Apostolos Tsiachristas; Sarah Wordsworth; Maureen Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2021-04-16       Impact factor: 4.981

10.  Innovative assessment of inpatient and pulmonary drug costs for children with cystic fibrosis.

Authors:  Joseph F Levy; Marjorie A Rosenberg; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2016-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.